Market Intelligence, Clinical Progress, and High-Purity Reagents for Glaucoma, Neurological, and Oncology Applications.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CA2/CA-II drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CA2/CA-II Recombinant Protein (Full Length) Sequence Verified, High Purity (>95%), Endotoxin <1EU/μg. Zinc-binding integrity maintained. |
View CA2 Products |
| Active Site Mutants | CA2 Catalytic Mutants (H64A, H119A) For mechanism-of-action studies and selectivity validation. |
View CA2 Products |
| Gene Delivery | CA2 Promise-ORF / Lentivirus Full-length ORF for stable intracellular overexpression in HEK293. |
View CA2 Products |
| Benchmark Ab | Anti-CA2 Reference Antibody Recombinant monoclonal for Western/ELISA standardization. |
View CA2 Products |
| Validator | CA2 siRNA Set For knockdown verification and off-target specificity control. |
View CA2 Products |
| Related Target: CA9 | Carbonic Anhydrase IX Hypoxia-associated transmembrane isoform; Critical for selectivity counter-screening. |
View CA9 Products |
| Related Target: CA12 | Carbonic Anhydrase XII Tumor-associated isoform; Off-target liability assessment. |
View CA12 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity Screening (vs CA1, CA4, CA9, CA12) | Human/Mouse/Cyno CA2 + Homolog Panel proteins; Strictly verified by mass spec; >95% purity |
| Enzyme Kinetic Validation | Zinc-content stoichiometry confirmed; Theoretical MW match; Suitable for stopped-flow kinetics |
| Blood-Brain Barrier Penetration Studies | Native folding confirmed by circular dichroism; Structural integrity for CNS compound screening |
| Mechanistic Probe Development | Active Site Mutants (H64A, H119A) available for mechanistic differentiation |
Live CA2/CA-II R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for CA2/CA-II is undergoing a strategic shift from broad-spectrum inhibition to isoform-selective targeting. While first-generation sulfonamide inhibitors (acetazolamide, dorzolamide) dominate the glaucoma market, next-generation R&D focuses on blood-brain barrier penetration for epilepsy and neurodegenerative diseases, and tumor microenvironment modulation via pH regulation. As first-line therapies face generic competition, the next wave of R&D is targeting organ-specific delivery mechanisms and reduced off-target toxicity profiles. Additionally, targeted protein degradation (PROTAC) strategies are emerging for oncology and CNS indications.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Novartis, Alcon, Taro | Glaucoma, Edema, Epilepsy | Isoform Selectivity Panel (CA2 vs CA1/CA4/CA9/CA12) with high-purity proteins |
| Isoform-Specific Inhibitors | Emerging Biotech | Solid Tumors (pH regulation) | Ortholog Cross-reactivity (Human/Mouse/Cyno) for toxicology bridging |
| CNS-Penetrant Inhibitors | Neuroscience-focused Pharma | Neurodegeneration, Idiopathic Intracranial Hypertension | Active Site Integrity Validation (Zinc coordination confirmed) |
| PROTACs | Academic/Startup | Cancer | Intracellular Stability Assay (Need full-length native CA2 protein) |